Logo of Monash Ivf (ASX:MVF)Latest Monash Ivf (ASX:MVF) News

Page 1
Page 1 of 2

Market Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Prominence Energy doubled as hydrogen speculation drove the week’s biggest move, while takeover news lifted RAS Technology and Cleanaway.
Zip Co and several resource developers fell as investors weighed costs, capital needs and delivery risks.
Logan Eniac
24 Oct 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

Monash IVF profit falls 41% as Australian market weakness tests FY27 recovery plan

Monash IVF Group’s underlying NPAT fell 41% to A$16.1 million in FY26, missing its recently reduced guidance as softer Australian IVF activity outweighed international growth. A second-half market-share recovery, lower planned capital spending and a new productivity program now carry the FY27 investment case.
Ada Torres
23 Oct 2026

Healthcare Wrap - Week 24 (8 June -> 12 June) 2026

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.
Logan Eniac
13 June 2026

Monash IVF Cuts FY26 Profit Forecast as Australian Market Softens but Gains Share

Monash IVF lowers its FY26 underlying NPAT guidance to $17-18 million, citing a 4.7% drop in Australian stimulated IVF cycles. Despite this, the company has expanded its national market share to 20.1% and seen international volume growth.
Ada Torres
12 June 2026

Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.
Logan Eniac
25 Apr 2026

Monash IVF Board Rejects $0.90 Per Share Takeover Offer as Undervalued

Monash IVF has turned down a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, citing significant undervaluation and confidence in its new CEO’s growth strategy.
Ada Torres
20 Apr 2026

Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.
Logan Eniac
18 Apr 2026

Monash IVF Consortium Raises Offer to $0.90 Per Share with Stringent Conditions

Monash IVF has received a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, upping the ante from a previous $0.80 offer. The deal hinges on exclusivity and unanimous board support, with no guarantee of completion.
Ada Torres
13 Apr 2026

Monash IVF Firmly Rejects $0.80 Per Share Takeover Bid from Genesis Consortium

Monash IVF has decisively turned down a non-binding acquisition offer valuing its shares at $0.80, citing significant undervaluation and uncertain financing. The Board signals openness only to proposals that deliver compelling shareholder value.
Ada Torres
24 Nov 2025

Monash IVF Posts Revenue Growth Amid NPAT Dip, Eyes Innovation and Cost Control

Monash IVF Group reported a 6.7% revenue increase to $271.9 million for FY25, alongside an 8.1% decline in underlying NPAT, aligning with prior guidance. The company outlined a cautious FY26 outlook focused on innovation, doctor retention, and cost management.
Ada Torres
20 Nov 2025

Monash IVF Navigates FY25 Growth Amid Challenges and Leadership Shift

Monash IVF Group reported solid FY25 revenue and EBITDA growth despite sector softness and clinical incidents, while announcing a leadership transition and dividend pause.
Ada Torres
20 Nov 2025